U.S. markets close in 11 minutes

Eiger BioPharmaceuticals, Inc. (EIGR)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
8.06-0.03 (-0.37%)
As of 3:43PM EDT. Market open.

Eiger BioPharmaceuticals, Inc.

2155 Park Boulevard
Palo Alto, CA 94306
United States
650 272 6138

Full Time Employees31

Key Executives

NameTitlePayExercisedYear Born
Mr. David A. Cory M.B.A., R.Ph., R.Ph, MBABus. Founder, Pres, CEO & Director1MN/A1964
Dr. Jeffrey S. GlennFounder, Scientific Advisor & Independent Director57.5kN/A1963
Mr. Sriram Ryali M.B.A.Chief Financial Officer567.12kN/A1981
Dr. Evan LohCEO of Paratek Pharmaceuticals & Director60kN/A1959
Mr. Eldon C. Mayer III, M.B.A.Exec. VP & Chief Commercial Officer657.15kN/A1961
Dr. Ingrid C. ChoongSr. VP of Clinical Devel.N/AN/AN/A
Mr. James P. Shaffer M.B.A., MBAChief Bus. OfficerN/AN/A1967
Dr. Stephana E. PattonConsultantN/AN/A1971
Mr. Rich Franco M.B.A.Sr. VP & Progeria Program LeadN/AN/AN/A
Dr. Colin HislopSr. VP of Clinical & Devel. OperationsN/AN/A1958
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. The company was founded in 2008 and is headquartered in Palo Alto, California.

Corporate Governance

Eiger BioPharmaceuticals, Inc.’s ISS Governance QualityScore as of April 30, 2021 is 7. The pillar scores are Audit: 2; Board: 5; Shareholder Rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.